Webatai Life Sciences Biotechnology Research Healing mental health disorders so that everyone, everywhere can live a more fulfilled life. See jobs Follow View all 143 employees WebMar 6, 2024 · atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression NEW YORK and BERLIN, Jan. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, …
Atai IPO Jumps In Debut After Pricing At High End In Upsized …
WebApr 12, 2024 · The trading price of Atai Life Sciences N.V. (NASDAQ:ATAI) closed higher on Tuesday, April 11, closing at $1.78, 5.33% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $1.735 and $1.8407. Web16 hours ago · Clinical-stage biopharma company atai Life Sciences (NASDAQ:ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception … sphere outline images
atai Life Sciences - ATAI - Stock Price Today - Zacks
WebApr 13, 2024 · The company is a majority-owned subsidiary of atai Life Sciences AG. PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects. WebNov 23, 2024 · NEW YORK, Nov. 23, 2024 /PRNewswire/ -- ATAI Life Sciences ("ATAI" or the "Company"), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health ... WebApr 9, 2024 · In this article. ATAI Life Sciences, a Peter Thiel-backed biopharmaceutical company developing psychedelic drugs to treat mental health, has taken a majority … sphere overlap unity